These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34014797)

  • 1. Bisphosphonates Related Ocular Side Effects: A Case Series and Review of Literature.
    Gendelman O; Tripto-Shkolnik L; Vered I; Lidar M
    Ocul Immunol Inflamm; 2022; 30(7-8):1995-1999. PubMed ID: 34014797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [BISPHOSPHONATES AND OCULAR INFLAMMATION].
    Rappoport D; Leiba H
    Harefuah; 2017 Feb; 156(2):71-73. PubMed ID: 28551891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Side Effects of Bisphosphonates: A Review of Literature.
    Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
    J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonate-Induced Orbital Inflammation: A Case Series and Review.
    Pirbhai A; Rajak SN; Goold LA; Cunneen TS; Wilcsek G; Martin P; Leibovitch I; Selva D
    Orbit; 2015; 34(6):331-5. PubMed ID: 26540241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory eye reactions in patients treated with bisphosphonates and other osteoporosis medications: cohort analysis using a national prescription database.
    Pazianas M; Clark EM; Eiken PA; Brixen K; Abrahamsen B
    J Bone Miner Res; 2013 Mar; 28(3):455-63. PubMed ID: 23044864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonates for Paget's disease of bone in adults.
    Corral-Gudino L; Tan AJ; Del Pino-Montes J; Ralston SH
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD004956. PubMed ID: 29192423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risedronate: a new oral bisphosphonate.
    Umland EM; Boyce EG
    Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bilateral uveitis secondary to bisphosphonate therapy.
    Tan YL; Sims J; Chee SP
    Ophthalmologica; 2009; 223(3):215-6. PubMed ID: 19221448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
    Murad OM; Arora S; Farag AF; Guber HA
    Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Bisphosphonate-associated osteonecrosis of the jaw in rheumatology: a systematic review].
    Capsoni F
    Reumatismo; 2008; 60(1):6-13. PubMed ID: 18432320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
    Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
    Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: profound hypocalcemia, rapid response, and prolonged remission.
    Stuckey BG; Lim EM; Kent GN; Ward LC; Gutteridge DH
    J Bone Miner Res; 2001 Sep; 16(9):1719-23. PubMed ID: 11547843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
    Keren S; Leibovitch I; Ben Cnaan R; Neudorfer M; Fogel O; Greenman Y; Shulman S; Zur D; Habot-Wilner Z
    Acta Ophthalmol; 2019 Aug; 97(5):e792-e799. PubMed ID: 30816018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonate use in the treatment of Paget's disease of the bone: analysis of claims in a large database.
    Dolgitser M; Stern L; Katz LM; Doyle JJ; Omar M; Seton M; Kahler KH
    Manag Care Interface; 2007 Feb; 20(2):33-40. PubMed ID: 17405580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emerging oral complication of supportive cancer therapy.
    Migliorati CA; Schubert MM; Peterson DE; Seneda LM
    Cancer; 2005 Jul; 104(1):83-93. PubMed ID: 15929121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonates to reduce bone fractures in stage 3B+ chronic kidney disease: a propensity score-matched cohort study.
    Robinson DE; Ali MS; Strauss VY; Elhussein L; Abrahamsen B; Arden NK; Ben-Shlomo Y; Caskey F; Cooper C; Dedman D; Delmestri A; Judge A; Javaid MK; Prieto-Alhambra D
    Health Technol Assess; 2021 Mar; 25(17):1-106. PubMed ID: 33739919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Avascular mandibular osteonecrosis in association with bisphosphonate therapy: a report on four patients.
    Friedrich RE; Blake FA
    Anticancer Res; 2007; 27(4A):1841-5. PubMed ID: 17649782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-associated orbital inflammation--a case report and review.
    Peterson JD; Bedrossian EH
    Orbit; 2012 Apr; 31(2):119-23. PubMed ID: 22489855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonate-Induced Acute Orbital Inflammation in a Patient With Underlying Thyroid Ophthalmopathy.
    Yu J; Guan J
    Cureus; 2020 Dec; 12(12):e12024. PubMed ID: 33457127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.